Vascular endothelial growth factor A

Vascular endothelial growth factor A
Name	Vascular endothelial growth factor A
Uniprot	P15692
Gene	VEGFA
Organism	Homo sapiens

Vascular endothelial growth factor A is a secreted signaling protein central to angiogenesis, vasculogenesis, and vascular permeability. Discovered through work that connected tumor growth to neovascularization, it has been studied across molecular biology, physiology, oncology, and ophthalmology. Its medical relevance spans targeted cancer therapies, retinal disease treatments, and investigations by institutions such as National Institutes of Health, Food and Drug Administration, World Health Organization, and research centers at Harvard University and Stanford University.

Structure and isoforms

VEGFA is encoded by the VEGFA gene on human chromosome 6 and yields multiple peptide isoforms through alternative splicing documented in literature from groups at Cold Spring Harbor Laboratory, Max Planck Society, Salk Institute, and Shanghai Jiao Tong University. Structural biology studies using methods from European Molecular Biology Laboratory, Protein Data Bank, and crystallography teams at University of Cambridge and Massachusetts Institute of Technology resolved homodimeric arrangements and heparin-binding sites. Isoforms commonly designated by amino acid length (e.g., 121, 165, 189) differ in heparan sulfate affinity and extracellular matrix interactions, informed by work at Johns Hopkins University, University of Oxford, Karolinska Institute, and UCSF. Post-translational modifications characterized by researchers at Johns Hopkins Bloomberg School of Public Health and University College London influence receptor binding to tyrosine kinase receptors first cloned in studies at Scripps Research and University of California, San Diego.

Function and signaling pathways

VEGFA engages receptors such as VEGFR-1 and VEGFR-2 to activate intracellular cascades mapped by labs at Yale University, Columbia University, University of Pennsylvania, and Princeton University. Downstream effectors include PLCγ, PI3K–AKT, and MAPK pathways elucidated in reports originating from California Institute of Technology, Weill Cornell Medicine, University of Michigan, and University of Toronto. Crosstalk with co-receptors like neuropilin-1 and interactions with integrin complexes were detailed in experiments at MIT Koch Institute, Dana-Farber Cancer Institute, Fred Hutchinson Cancer Research Center, and Northwestern University. Signaling outcomes—endothelial cell proliferation, migration, survival, and permeability—are central themes in studies affiliated with Memorial Sloan Kettering Cancer Center, Vanderbilt University Medical Center, Cedars-Sinai Medical Center, and University of Chicago.

Regulation and expression

Transcriptional control of VEGFA involves factors such as HIF-1α characterized by groups at Rockefeller University, Imperial College London, University of Oxford, and ETH Zurich. Hypoxia-driven upregulation was framed in seminal work from University of California, San Francisco and University of British Columbia. MicroRNA-mediated regulation, epigenetic modifications, and promoter analyses were advanced by teams at Cold Spring Harbor Laboratory, University of California, Berkeley, Max Delbrück Center for Molecular Medicine, and Seoul National University. Cytokine and growth factor stimuli studied at Mayo Clinic, Cleveland Clinic, Institut Pasteur, and NIH Clinical Center demonstrate tissue-specific expression patterns in organs investigated by researchers at Karolinska University Hospital, Tokyo University, University of Sydney, and McGill University.

Role in physiology and development

VEGFA is essential for embryonic vasculogenesis and organogenesis as shown in genetic models from University of Cambridge, Stanford University School of Medicine, Harvard Medical School, and University of California, Los Angeles. Studies using knockout mice at The Jackson Laboratory, European Molecular Biology Laboratory, and Max Planck Institute revealed lethal vascular defects and impaired myocardial and placental development. Adult physiological roles include wound healing, exercise-induced angiogenesis, and menstruation-related vascular remodeling investigated by teams at University of Copenhagen, University of Melbourne, Peking University, and University of Edinburgh. Interactions with pericytes, endothelial progenitor cells, and extracellular matrix components were explored in collaborations involving Nanyang Technological University, University of Zurich, King’s College London, and University of Heidelberg.

Clinical significance and disease associations

Aberrant VEGFA expression is implicated in pathologies such as solid tumor angiogenesis, age-related macular degeneration, diabetic retinopathy, rheumatoid arthritis, and psoriasis, with clinical research contributions from Memorial Sloan Kettering Cancer Center, Moorfields Eye Hospital, Bascom Palmer Eye Institute, and Dana-Farber Cancer Institute. Elevated VEGFA correlates with metastasis and poor prognosis in cancers studied at MD Anderson Cancer Center, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, University College London Hospitals, and Mount Sinai Hospital. Role in ischemic heart disease, stroke, and peripheral artery disease was examined by investigators at Cleveland Clinic Foundation, Brigham and Women’s Hospital, Karolinska University Hospital, and Royal Brompton Hospital. Biomarker studies and clinical trials have been coordinated by networks including European Society for Medical Oncology, American Society of Clinical Oncology, Association for Research in Vision and Ophthalmology, and National Comprehensive Cancer Network.

Therapeutic targeting and drugs

Therapeutic blockade of VEGFA signaling is a cornerstone of treatments developed by pharmaceutical and biotech firms such as Genentech, Roche, Novartis, Regeneron Pharmaceuticals, and Bayer. Monoclonal antibodies and fusion proteins—invented and trialed in collaborations with Amgen, Eli Lilly and Company, Pfizer, and Sanofi—include agents that neutralize ligand activity or inhibit receptor tyrosine kinases elaborated in trials registered by ClinicalTrials.gov and overseen by regulatory bodies like European Medicines Agency, Food and Drug Administration, and Medicines and Healthcare products Regulatory Agency. Key clinical applications cover oncology agents for colorectal, lung, and renal cancers tested at NCI, Royal Marsden Hospital, and Peter MacCallum Cancer Centre, and ophthalmic intravitreal therapies for macular degeneration studied at Massachusetts Eye and Ear, Wills Eye Hospital, and Johns Hopkins Wilmer Eye Institute. Resistance mechanisms, adverse effects such as hypertension and thromboembolic events, and combination strategies with immunotherapies are active research topics at Fred Hutchinson Cancer Research Center, Institut Curie, Scripps Research Institute, and University of Texas MD Anderson Cancer Center.

Category:Growth factors